Moore RD - Search Results

1

Telemedicine and visit completion among people with HIV during the coronavirus disease 2019 pandemic compared with prepandemic.

El-Nahal WG, Shen NM, Keruly JC, Jones JL, Fojo AT, Lau B, Manabe YC, Moore RD, Gebo KA, Lesko CR, Chander G. El-Nahal WG, et al. Among authors: moore rd. AIDS. 2022 Mar 1;36(3):355-362. doi: 10.1097/QAD.0000000000003119. AIDS. 2022. PMID: 34711737 Free PMC article.

2

Association of medical insurance and other factors with receipt of antiretroviral therapy.

Keruly JC, Conviser R, Moore RD. Keruly JC, et al. Among authors: moore rd. Am J Public Health. 2002 May;92(5):852-7. doi: 10.2105/ajph.92.5.852. Am J Public Health. 2002. PMID: 11988459 Free PMC article.

3

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. Among authors: moore rd. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

4

Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings.

Spacek LA, Griswold M, Quinn TC, Moore RD. Spacek LA, et al. Among authors: moore rd. AIDS. 2003 Jun 13;17(9):1311-7. doi: 10.1097/00002030-200306130-00005. AIDS. 2003. PMID: 12799552

5

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

6

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

7

Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51. doi: 10.1097/00126334-200401010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 14707791

8

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Among authors: moore rd. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

9

Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.

Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Feb 20;18(3):541-6. doi: 10.1097/00002030-200402200-00022. AIDS. 2004. PMID: 15090808

10

Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.

Lucas GM, Gallant JE, Moore RD. Lucas GM, et al. Among authors: moore rd. AIDS. 2004 Jul 23;18(11):1539-48. doi: 10.1097/01.aids.0000131339.68666.1a. AIDS. 2004. PMID: 15238772

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

931 results

Search Page

Filters